Quotations are not that big of deal, I have traded grey sheet stocks, no bid/no-ask stocks. I own some. Made great money on one last 12 weeks.
It is not much different than today's L-2, where you know what the official MM liars-poker bids and asks are on a stock, LOL.
It is pretty obvious Hovis intentionally left the CE up, to limit speculation on the stock based on partial / incomplete information, since the custodian already 8-K told the SEC the entire business plan for MILV, that is now NDTP, and that is the last of a long list of items on the 2019 shareholder letter, to go back to SEC reporting and kiss the existing SEC 15-12g filing that protects NDTP good by.
That could not be done safely with reporting the financials of a shell last year using an OTC Alt-financial filing.
In fact it would have risked the SEC's wrath IMO.
It requires, at a minimum an SEC super 8-K/S-1 filing with an audited 10-K.
And to stay on OTC with $500,000,000.00 to $700 Million dollar cap for a biotech would be sure madness.
That implies an SEC 1-A uplist filing to NYSE overnight leaving no time to shop for cheap shares.
Also, the insider shares can not be sold until 12 months after the financials are filed. So they have 500 to 700 Million dollars more in shares at risk, than we do.
I am invested here based on my own DD. Which I trust.
News 
Market Data 
Discover 
